

Row No	REC No	IRAS No	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
1	16/NW/0086	198831	A Phase 1, Single-Agent, Dose-Escalation, Pharmacokinetic (PK)-Pharmacodynamic (PD) Study of Avelumab in Patients with Advanced or Refractory Classical Hodgkin Lymphoma	Number Agreed	2	2	Date Agreed	09/05/2018	4	09/05/2018	4	Recruitment Finished
2	15/YH/0535	190077	A multicenter, randomized, open label, parallel group study comparing pre-discharge and post-discharge treatment initiation with LCZ696 in heart failure patients with reduced ejection fraction hospitalized for an acute decompensation event (ADHF) (th	Number Agreed	5	5	Date Agreed	08/12/2017	3	08/12/2017	3	Recruitment Finished
3	16/LO/1386	199366	A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment with Elamipretide in Patients Hospitalized with Congestion due to Heart Failure	Number Agreed	6	6	Date Agreed	17/11/2017	1	17/11/2017	1	Recruitment Finished
4	15/LO/1681	185104	A double blind, randomized, placebo-controlled trial evaluating efficacy and safety of oral nintedanib, 150 mg twice daily for 52 weeks (with follow up until last patient out up to a maximum of 2 years) in patients with Systemic Sclerosis associated	Number Agreed	1	1	Date Agreed	19/01/2018	0	19/01/2018	0	Recruitment Finished
5	17/EM/0275	227425	A Multi-center, Double-blind, Randomized, Three-Arm, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants	Number Agreed	5	5	Date Agreed	25/04/2018	5	25/04/2018	5	Recruitment Finished
6	17/EM/0190	219055	A Phase 3b, Randomized, Active Comparator, Open-label, Multicenter Study to Compare the Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and to Glimepiride as Add-on Therapy to Metformin in Patients with Type 2 Diabetes	Number Agreed	10	10	Date Agreed	16/10/2017	0	16/10/2017	0	Recruitment Finished
7	17/EM/0014	219556	Prospective Clinical Investigation for a Randomized, Controlled, Multicenter Non-inferiority Study Comparing Standard Wound Closure Technique with Drains (control) to Standard Wound Closure Techniques with TissuGlu? and No Drains (test) in Mastectomy	Number Agreed	15	15	Date Agreed	31/12/2017	10	31/12/2017	10	Recruitment Finished
8	14/LO/1443	149317	A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Subjects on Stable Dialysis	Number Agreed	2	2	Date Agreed	10/05/2018	5	10/05/2018	5	Recruitment Finished
9	15/LO/0545	172357	Clinical and device functional assessment of real world ICD patients - RTSY03	Number Agreed	10	10	Date Agreed	31/10/2017	11	31/10/2017	11	Recruitment Finished
10	16/YH/0074	199143	Evaluation of a Multi-Electrode Linear Type Catheter (D-1368-01-SI) for Endocardial Ablation of Patients with Persistent Atrial Fibrillation.	Number Agreed	8	8	Date Agreed	29/11/2017	7	29/11/2017	7	Recruitment Finished
11	16/LO/1717	212505	A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia	Number Agreed	3	3	Date Agreed	25/10/2017	0	25/10/2017	0	Recruitment Finished
12	13/LO/0867	126972	1199.93 - 1199.93 LUME-Meso Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed / cisplatin fol	Number Agreed	5	5	Date Agreed	08/01/2018	10	08/01/2018	10	Recruitment Finished
13	14/LO/1486	159398	A Phase 1b/2, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination with MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIb to IVM1c Melanoma (MASTERKEY-265)	Number Agreed	5	5	Date Agreed	30/03/2018	2	30/03/2018	2	Recruitment Finished
14	15/WS/0135	183471	A Phase 1b Dose Escalation and Dose Expansion Study of ONO/GS-4059 Combined with Idelalisib in Subjects with B-cell Malignancies	Number Agreed	6	6	Date Agreed	03/05/2018	25	03/05/2018	25	Recruitment Finished

Row No	REC No	IRAS No	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
15	15/EM/0179	177000	Understanding Outcomes with the EMBLEMT S-ICD in Primary Prevention Patients with Low Ejection Fraction	Number Agreed	15	15	Date Agreed	28/02/2018	7	28/02/2018	7	Recruitment Finished
16	16/LO/0092	194133	A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR DIFFUSE LARGE B-CELL LYMPHOMA	Number Agreed	4	4	Date Agreed	01/07/2021	6	24/08/2018	6	Recruitment Finished
17	15/LO/2100	192155	RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY EVALUATING TAS-102 PLUS	Number Agreed	4	4	Date Agreed	30/11/2017	3	30/11/2017	3	Recruitment Finished
18	16/LO/0423	198451	A Phase I trial of SRA737 (a CHK1 inhibitor) administered orally in subjects with advanced cancer	Number Agreed	10	10	Date Agreed	01/07/2018	3	01/07/2018	3	Recruitment Finished
19	16/LO/0595	198560	monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib plus Trastuzumab with or without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice plus Trastuzumab in Women with HR+, HER2	Number Agreed	2	2	Date Agreed	01/02/2018	2	01/02/2018	2	Recruitment Finished
20	16/EE/0372	212494	DETECTION OF METHACHOLINE CHALLENGE INDUCED ASTHMA SYMPTOMS USING A NOVEL DEVICE.	Number Agreed	20	20	Date Agreed	13/11/2017	0	13/11/2017	0	Recruitment Finished
21	16/YH/0454	211679	A prospective multi-centre observational study to evaluate the capabilities of a portable magnetocardiograph device to rule-out acute coronary syndrome in patients who present to the emergency department with chest pain symptoms consistent with ACS:	Number Agreed	175	175	Date Agreed	25/03/2018	82	25/03/2018	82	Recruitment Finished
22	17/SC/0201	209172	IP Rollover Study (XRuST): An Open-Label, Rollover Study	Number Agreed	1	1	Date Agreed	24/05/2018	1	24/05/2018	1	Recruitment Finished
23	17/LO/0065	219950	A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600 mutant	Number Agreed	3	3	Date Agreed	21/12/2020	2	07/06/2018	2	Recruitment Finished
24	16/EE/0463	214371	An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced	Number Agreed	5	5	Date Agreed	16/10/2017	2	16/10/2017	2	Recruitment Finished
25	17/SC/0294	224828	Title: A Phase III Randomised Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Neoadjuvant Anthracycline/Nab-paclitaxel Based Chemotherapy Compared with Placebo and Chemotherapy in Patients with P	Number Agreed	3	3	Date Agreed	12/06/2018	1	12/06/2018	1	Recruitment Finished
26	17/NE/0115	218417	Phase II study of Pirfenidone vs placebo in patients with fibrotic ILD that cannot be classified with moderate or high confidence into any other category of fibrotic IP by Multidisciplinary Team (MDT) review (?unclassifiable? ILD).	Number Agreed	2	2	Date Agreed	26/04/2018	2	26/04/2018	2	Recruitment Finished
27	16/WM/0473	213847	Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Advanced Malignancies	Number Agreed	11	11	Date Agreed	31/03/2018	0	31/03/2018	0	Recruitment Finished
28	17/LO/0249	220398	A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESIS INHIBI	Number Agreed	5	5	Date Agreed	19/04/2018	5	19/04/2018	5	Recruitment Finished

Row No	REC No	IRAS No	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
29	17/SC/0016	218645	A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin as First Line Therapy in unresectable Pleural Mesothelioma	Number Agreed	6	6	Date Agreed	22/02/2018	8	22/02/2018	8	Recruitment Finished
30	17/SC/0242	222650	Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Intravenous FDY-5301 in Acute Myocardial Infarction (Protocol No. FDY-5301-201)	Number Agreed	4	4	Date Agreed	30/06/2018	12	30/06/2018	12	Recruitment Finished
31	16/WM/0512	218042	A Phase 1, open-label, randomised, repeat dose parallel group study to evaluate the pharmacokinetics, safety and tolerability of ferric maltol at three dosage levels in paediatric subjects (aged 10-17) with iron deficiency (with or without Anaemia)	Number Agreed	3	3	Date Agreed	31/12/2017	6	31/12/2017	6	Recruitment Finished
32	17/LO/0504	224298	An open-label, single arm, repeat dose, multi-centre study to evaluate the use of an autoinjector for the subcutaneous administration of mepolizumab in subjects with severe eosinophilic asthma	Number Agreed	2	2	Date Agreed	07/02/2018	2	07/02/2018	2	Recruitment Finished
33	18/ES/0013	240837	PRospective Observation of aortic reGuRgitation aftEr TAVI and progreSS over time: PROGRESS PVL Registry	Number Agreed	6	6	Date Agreed	30/07/2018	3	30/07/2018	3	Recruitment Finished
34	17/EE/0264	228153	POSEIDON - A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Me	Number Agreed	6	6	Date Agreed	07/08/2018	7	07/08/2018	7	Recruitment Finished
35	17/YH/0345	233852	A phase 3, randomised, multicentre study of subcutaneous vs intravenous administration of daratumumab in subjects with relapsed or refractory multiple myeloma	Number Agreed	5	5	Date Agreed	20/06/2018	3	20/06/2018	3	Recruitment Finished
36	17/EM/0055	222279	A Randomized, Double-Blind, Placebo controlled, Parallel Group Study of Patiromer for the Enablement of Spironolactone Use for Blood Pressure Control in Patients with Resistant Hypertension and Chronic Kidney Disease: Evaluation of Safety and Efficac	Number Agreed	3	3	Date Agreed	04/05/2018	1	04/05/2018	1	Recruitment Finished
37	16/EM/0007		Global multicenter, open-label, randomized, event-driven, active-controlled study comparing a rivAroxaban-based	Number Agreed	12	12	Date Agreed	02/10/2017	4	02/10/2017	4	Recruitment Finished